301
|
Ablikim M, Achasov MN, Ai XC, Albayrak O, Albrecht M, Ambrose DJ, Amoroso A, An FF, An Q, Bai JZ, Ferroli RB, Ban Y, Bennett DW, Bennett JV, Bertani M, Bettoni D, Bian JM, Bianchi F, Boger E, Boyko I, Briere RA, Cai H, Cai X, Cakir O, Calcaterra A, Cao GF, Cetin SA, Chang JF, Chelkov G, Chen G, Chen HS, Chen HY, Chen JC, Chen ML, Chen SJ, Chen X, Chen XR, Chen YB, Cheng HP, Chu XK, Cibinetto G, Dai HL, Dai JP, Dbeyssi A, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Du SX, Duan PF, Eren EE, Fan JZ, Fang J, Fang SS, Fang X, Fang Y, Fava L, Feldbauer F, Felici G, Feng CQ, Fioravanti E, Fritsch M, Fu CD, Gao Q, Gao XY, Gao Y, Gao Z, Garzia I, Geng C, Goetzen K, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo Y, Guo YP, Haddadi Z, Hafner A, Han S, Han YL, Hao XQ, Harris FA, He KL, He ZY, Held T, Heng YK, Hou ZL, Hu C, Hu HM, Hu JF, Hu T, Hu Y, Huang GM, Huang GS, Huang HP, Huang JS, Huang XT, Huang Y, Hussain T, Ji Q, Ji QP, Ji XB, Ji XL, Jiang LL, Jiang LW, Jiang XS, Jiang XY, Jiao JB, Jiao Z, Jin DP, Jin S, Johansson T, Julin A, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kavatsyuk M, Ke BC, Kiese P, Kliemt R, Kloss B, Kolcu OB, Kopf B, Kornicer M, Kühn W, Kupsc A, Lange JS, Lara M, Larin P, Leng C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li HB, Li JC, Li J, Li K, Li K, Li L, Li PR, Li T, Li WD, Li WG, Li XL, Li XM, Li XN, Li XQ, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Lin DX, Liu BJ, Liu CX, Liu FH, Liu F, Liu F, Liu HB, Liu HH, Liu HH, Liu HM, Liu J, Liu JB, Liu JP, Liu JY, Liu K, Liu KY, Liu LD, Liu PL, Liu Q, Liu SB, Liu X, Liu XX, Liu YB, Liu ZA, Liu Z, Liu Z, Loehner H, Lou XC, Lu HJ, Lu JG, Lu RQ, Lu Y, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lv M, Lyu XR, Ma FC, Ma HL, Ma LL, Ma QM, Ma T, Ma XN, Ma XY, Maas FE, Maggiora M, Mao YJ, Mao ZP, Marcello S, Messchendorp JG, Min J, Min TJ, Mitchell RE, Mo XH, Mo YJ, Morales CM, Moriya K, Muchnoi NY, Muramatsu H, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu SL, Niu XY, Olsen SL, Ouyang Q, Pacetti S, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Poling R, Prasad V, Pu YN, Qi M, Qian S, Qiao CF, Qin LQ, Qin N, Qin XS, Qin Y, Qin ZH, Qiu JF, Rashid KH, Redmer CF, Ren HL, Ripka M, Rong G, Rosner C, Ruan XD, Santoro V, Sarantsev A, Savrié M, Schoenning K, Schumann S, Shan W, Shao M, Shen CP, Shen PX, Shen XY, Sheng HY, Song WM, Song XY, Sosio S, Spataro S, Sun GX, Sun JF, Sun SS, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Tapan I, Thorndike EH, Tiemens M, Ullrich M, Uman I, Varner GS, Wang B, Wang BL, Wang D, Wang DY, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang SG, Wang W, Wang XF, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZH, Wang ZY, Weber T, Wei DH, Wei JB, Weidenkaff P, Wen SP, Wiedner U, Wolke M, Wu LH, Wu Z, Xia LG, Xia Y, Xiao D, Xiao ZJ, Xie YG, Xiu QL, Xu GF, Xu L, Xu QJ, Xu QN, Xu XP, Yan L, Yan WB, Yan WC, Yan YH, Yang HJ, Yang HX, Yang L, Yang Y, Yang YX, Ye H, Ye M, Ye MH, Yin JH, Yu BX, Yu CX, Yu HW, Yu JS, Yuan CZ, Yuan WL, Yuan Y, Yuncu A, Zafar AA, Zallo A, Zeng Y, Zhang BX, Zhang BY, Zhang C, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang K, Zhang L, Zhang SH, Zhang XY, Zhang Y, Zhang YN, Zhang YH, Zhang YT, Zhang Y, Zhang ZH, Zhang ZP, Zhang ZY, Zhao G, Zhao JW, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao QW, Zhao SJ, Zhao TC, Zhao YB, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhou L, Zhou L, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu K, Zhu KJ, Zhu S, Zhu XL, Zhu YC, Zhu YS, Zhu ZA, Zhuang J, Zotti L, Zou BS, Zou JH. Observation of Z_{c}(3900)^{0} in e^{+}e^{-}→π^{0}π^{0}J/ψ. PHYSICAL REVIEW LETTERS 2015; 115:112003. [PMID: 26406823 DOI: 10.1103/physrevlett.115.112003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Indexed: 06/05/2023]
Abstract
Using a data sample collected with the BESIII detector operating at the BEPCII storage ring, we observe a new neutral state Z_{c}(3900)^{0} with a significance of 10.4σ. The mass and width are measured to be 3894.8±2.3±3.2 MeV/c^{2} and 29.6±8.2±8.2 MeV, respectively, where the first error is statistical and the second systematic. The Born cross section for e^{+}e^{-}→π^{0}π^{0}J/ψ and the fraction of it attributable to π^{0}Z_{c}(3900)^{0}→π^{0}π^{0}J/ψ in the range E_{c.m.}=4.19-4.42 GeV are also determined. We interpret this state as the neutral partner of the four-quark candidate Z_{c}(3900)^{±}.
Collapse
|
302
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 2015; 26:1877-1883. [PMID: 26141208 DOI: 10.1093/annonc/mdv276] [Citation(s) in RCA: 352] [Impact Index Per Article: 39.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Accepted: 06/16/2015] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). Findings from final overall survival (OS) analysis and assessment of post-study treatment impact are presented. PATIENTS AND METHODS Of 165 randomised patients, 82 received erlotinib and 72 gemcitabine plus carboplatin. Final OS analyses were conducted when 70% of deaths had occurred in the intent-to-treat population. Subgroup OS was analysed by Cox proportional hazards model and included randomisation stratification factors and post-study treatments. RESULTS Median OS was similar between the erlotinib (22.8 months) and chemotherapy (27.2 months) arms with no significant between-group differences in the overall population [hazard ratio (HR), 1.19; 95% confidence interval (CI) 0.83-1.71; P = 0.2663], the exon 19 deletion subpopulation (HR, 1.52; 95% CI 0.91-2.52; P = 0.1037) or the exon 21 L858 mutation subpopulation (HR, 0.92; 95% CI 0.55-1.54; P = 0.7392). More patients in the erlotinib arm versus the chemotherapy arm did not receive any post-study treatment (36.6% versus 22.2%). Patients who received sequential combination of EGFR-TKI and chemotherapy had significantly improved OS compared with those who received EGFR-TKI or chemotherapy only (29.7 versus 20.7 or 11.2 months, respectively; P < 0.0001). OS was significantly shorter in patients who did not receive post-study treatments compared with those who received subsequent treatments in both arms. CONCLUSION The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutant NSCLC patients, suggesting that erlotinib should be considered standard first-line treatment of EGFR mutant patients and EGFR-TKI treatment following first-line therapy also brings significant benefits to those patients. CLINICALTRIALSGOV IDENTIFIER NCT00874419.
Collapse
|
303
|
Ablikim M, Achasov MN, Ai XC, Albayrak O, Albrecht M, Ambrose DJ, Amoroso A, An FF, An Q, Bai JZ, Ferroli RB, Ban Y, Bennett DW, Bennett JV, Bertani M, Bettoni D, Bian JM, Bianchi F, Boger E, Boyko I, Briere RA, Cai H, Cai X, Cakir O, Calcaterra A, Cao GF, Cetin SA, Chang JF, Chelkov G, Chen G, Chen HS, Chen HY, Chen JC, Chen ML, Chen SJ, Chen X, Chen XR, Chen YB, Cheng HP, Chu XK, Cibinetto G, Dai HL, Dai JP, Dbeyssi A, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Du SX, Duan PF, Eren EE, Fan JZ, Fang J, Fang SS, Fang X, Fang Y, Fava L, Feldbauer F, Felici G, Feng CQ, Fioravanti E, Fritsch M, Fu CD, Gao Q, Gao XY, Gao Y, Gao Z, Garzia I, Geng C, Goetzen K, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo Y, Guo YP, Haddadi Z, Hafner A, Han S, Han YL, Hao XQ, Harris FA, He KL, He ZY, Held T, Heng YK, Hou ZL, Hu C, Hu HM, Hu JF, Hu T, Hu Y, Huang GM, Huang GS, Huang HP, Huang JS, Huang XT, Huang Y, Hussain T, Ji Q, Ji QP, Ji XB, Ji XL, Jiang LL, Jiang LW, Jiang XS, Jiang XY, Jiao JB, Jiao Z, Jin DP, Jin S, Johansson T, Julin A, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kavatsyuk M, Ke BC, Kiese P, Kliemt R, Kloss B, Kolcu OB, Kopf B, Kornicer M, Kühn W, Kupsc A, Lange JS, Lara M, Larin P, Leng C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li HB, Li JC, Li J, Li K, Li K, Li L, Li PR, Li T, Li WD, Li WG, Li XL, Li XM, Li XN, Li XQ, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Lin DX, Liu BJ, Liu CX, Liu FH, Liu F, Liu F, Liu HB, Liu HH, Liu HH, Liu HM, Liu J, Liu JB, Liu JP, Liu JY, Liu K, Liu K, Liu KY, Liu LD, Liu PL, Liu Q, Liu SB, Liu X, Liu XX, Liu YB, Liu ZA, Liu Z, Liu Z, Loehner H, Lou XC, Lu HJ, Lu JG, Lu RQ, Lu Y, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lv M, Lyu XR, Ma FC, Ma HL, Ma LL, Ma QM, Ma T, Ma XN, Ma XY, Maas FE, Maggiora M, Mao YJ, Mao ZP, Marcello S, Messchendorp JG, Min J, Min TJ, Mitchell RE, Mo XH, Mo YJ, Morales CM, Moriya K, Muchnoi NY, Muramatsu H, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu SL, Niu XY, Olsen SL, Ouyang Q, Pacetti S, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Poling R, Prasad V, Pu YN, Qi M, Qian S, Qiao CF, Qin LQ, Qin N, Qin XS, Qin Y, Qin ZH, Qiu JF, Rashid KH, Redmer CF, Ren HL, Ripka M, Rong G, Rosner C, Ruan XD, Santoro V, Sarantsev A, Savrié M, Schoenning K, Schumann S, Shan W, Shao M, Shen CP, Shen PX, Shen XY, Sheng HY, Song WM, Song XY, Sosio S, Spataro S, Sun GX, Sun JF, Sun SS, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Tapan I, Thorndike EH, Tiemens M, Ullrich M, Uman I, Varner GS, Wang B, Wang BL, Wang D, Wang DY, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang SG, Wang W, Wang XF, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZH, Wang ZY, Weber T, Wei DH, Wei JB, Weidenkaff P, Wen SP, Wiedner U, Wolke M, Wu LH, Wu Z, Xia LG, Xia Y, Xiao D, Xiao ZJ, Xie YG, Xiu QL, Xu GF, Xu L, Xu QJ, Xu QN, Xu XP, Yan L, Yan WB, Yan WC, Yan YH, Yang HJ, Yang HX, Yang L, Yang Y, Yang YX, Ye H, Ye M, Ye MH, Yin JH, Yu BX, Yu CX, Yu HW, Yu JS, Yuan CZ, Yuan WL, Yuan Y, Yuncu A, Zafar AA, Zallo A, Zeng Y, Zhang BX, Zhang BY, Zhang C, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang K, Zhang L, Zhang SH, Zhang XY, Zhang Y, Zhang YN, Zhang YH, Zhang YT, Zhang Y, Zhang ZH, Zhang ZP, Zhang ZY, Zhao G, Zhao JW, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao QW, Zhao SJ, Zhao TC, Zhao YB, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhou L, Zhou L, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu K, Zhu KJ, Zhu S, Zhu XL, Zhu YC, Zhu YS, Zhu ZA, Zhuang J, Zotti L, Zou BS, Zou JH. Observation and Spin-Parity Determination of the X(1835) in J/ψ→γK_{S}^{0}K_{S}^{0}η. PHYSICAL REVIEW LETTERS 2015; 115:091803. [PMID: 26371642 DOI: 10.1103/physrevlett.115.091803] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Indexed: 06/05/2023]
Abstract
We report an observation of the process J/ψ→γX(1835)→γK_{S}^{0}K_{S}^{0}η at low K_{S}^{0}K_{S}^{0} mass with a statistical significance larger than 12.9σ using a data sample of 1.31×10^{9} J/ψ events collected with the BESIII detector. In this region of phase space the K_{S}^{0}K_{S}^{0} system is dominantly produced through the f_{0}(980). By performing a partial wave analysis, we determine the spin parity of the X(1835) to be J^{PC}=0^{-+}. The mass and width of the observed X(1835) are 1844±9(stat)_{-25}^{+16}(syst) MeV/c^{2} and 192_{-17}^{+20}(stat)_{-43}^{+62}(syst) MeV, respectively, which are consistent with the results obtained by BESIII in the channel J/ψ→γπ^{+}π^{-}η^{'}.
Collapse
|
304
|
Tai DS, Hu C, Lee CCI, Martinez M, Cantero G, Kim EH, Tarantal AF, Lipshutz GS. Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates: preliminary studies. Gene Ther 2015; 22:923-30. [PMID: 26333349 DOI: 10.1038/gt.2015.65] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2015] [Revised: 05/22/2015] [Accepted: 06/18/2015] [Indexed: 02/05/2023]
Abstract
Achieving persistent expression is a prerequisite for effective genetic therapies for inherited disorders. These proof-of-concept studies focused on adeno-associated virus (AAV) administration to newborn monkeys. Serotype rh10 AAV expressing ovalbumin and green fluorescent protein (GFP) was administered intravenously at birth and compared with vehicle controls. At 4 months postnatal age, a second injection was administered intramuscularly, followed by vaccination at 1 year of age with ovalbumin and GFP. Ovalbumin was highest 2 weeks post administration in the treated monkey, which declined but remained detectable thereafter; controls demonstrated no expression. Long-term AAV genome copies were present in myocytes. At 4 weeks, neutralizing antibodies to rh10 were present in the experimental animal only. With AAV9 administration at 4 months, controls showed transient ovalbumin expression that disappeared with the development of strong anti-ovalbumin and anti-GFP antibodies. In contrast, increased and maintained ovalbumin expression was noted in the monkey administered AAV at birth, without antibody development. After vaccination, the experimental monkey maintained levels of ovalbumin without antibodies, whereas controls demonstrated high levels of antibodies. These preliminary studies suggest that newborn AAV administration expressing secreted and intracellular xenogenic proteins may result in persistent expression in muscle, and subsequent vector administration can result in augmented expression without humoral immune responses.
Collapse
|
305
|
Lei H, Hu X, Zhu P, Chang X, Zeng Y, Hu C, Li H, Hu X. Nano-level position resolution for particle tracking in digital in-line holographic microscopy. J Microsc 2015; 260:100-6. [PMID: 26239892 DOI: 10.1111/jmi.12271] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Accepted: 04/30/2015] [Indexed: 11/30/2022]
Abstract
Three-dimensional particle tracking in biological systems is a quickly growing field, many techniques have been developed providing tracking characters. Digital in-line holographic microscopy is a valuable technique for particle tracking. However, the speckle noise, out-of-focus signals and twin image influenced the particle tracking. Here an adaptive noise reduction method based on bidimensional ensemble empirical mode decomposition is introduced into digital in-line holographic microscopy. It can eliminate the speckle noise and background of the hologram adaptively. Combined with the three-dimensional deconvolution approach in the reconstruction, the particle feature would be identified effectively. Tracking the fixed beads on the cover-glass with piezoelectric stage through multiple holographic images demonstrate the tracking resolution, which approaches 2 nm in axial direction and 1 nm in transverse direction. This would facilitate the development and use in the biological area such as living cells and single-molecule approaches.
Collapse
|
306
|
Chen LQ, Hu C, Peng J. F-158THE REQUIREMENT OF LYMPHADENECTOMY FOR OESOPHAGEAL CARCINOMA: COUNTING THE LEAST LYMPH NODE STATIONS IS MORE APPLICABLE. Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
307
|
Zhu C, Wang S, Wang B, Du F, Hu C, Li H, Feng Y, Zhu R, Mo M, Cao Y, Li A, Yu X. 17β-Estradiol up-regulates Nrf2 via PI3K/AKT and estrogen receptor signaling pathways to suppress light-induced degeneration in rat retina. Neuroscience 2015. [PMID: 26211446 DOI: 10.1016/j.neuroscience.2015.07.057] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Human age-related retinal diseases, such as age-related macular degeneration (AMD), are intimately associated with decreased tissue oxygenation and hypoxia. Different antioxidants have been investigated to reverse AMD. In the present study, we describe the antioxidant 17β-estradiol (βE2) and investigate its protective effects on retinal neurons. Fourteen days after ovariectomy, adult Sprague-Dawley rats were exposed to 8000-lux light for 12h to induce retinal degeneration. Reactive oxygen species (ROS) levels were assessed by confocal fluorescence microscopy using 2,7-dichlorofluorescein diacetate. Nuclear factor erythroid 2-related factor 2 (Nrf2) and antioxidant enzyme mRNA expression were detected by real-time PCR. Western blotting was used to evaluate NRF2 activation. NRF2 translocation was determined by immunohistochemistry, with morphological changes monitored by hematoxylin and eosin staining. Following light exposure, βE2 significantly reduced ROS production. βE2 also up-regulated NRF2 mRNA and protein levels, with maximal expression at 4 and 12h post-exposure, respectively. Interestingly, following βE2 administration, NRF2 was translocated from the cytoplasm to the nucleus, primarily in the outer nuclear layer. βE2 also up-regulated NRF2, which triggered phase-2 antioxidant enzyme expression (superoxide dismutases 1 and 2, catalase, glutaredoxins 1 and 2, and thioredoxins 1 and 2), reduced ROS production, and ameliorated retinal damage. However, the beneficial effects of βE2 were markedly suppressed by pretreatment with LY294002 or ICI182780, specific inhibitors of the phosphatidylinositol 3-kinase-Akt (PI3K/AKT), and estrogen receptor (ER) signaling pathways, respectively. Taken together, these observations suggest that βE2 exerts antioxidative effects following light-induced retinal degeneration potentially via NRF2 activation. This protective mechanism may depend on two pathways: a rapid, non-genomic-type PI3K/AKT response, and a genomic-type ER-dependent response. Our data provide evidence that βE2 is a potentially effective in the treatment of retinal degeneration diseases.
Collapse
|
308
|
Su J, Hu C, Yan X, Jin Y, Chen Z, Guan Q, Wang Y, Zhong D, Jansson C, Wang F, Schnürer A, Sun C. Expression of barley SUSIBA2 transcription factor yields high-starch low-methane rice. Nature 2015. [PMID: 26200336 DOI: 10.1038/nature14673] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Atmospheric methane is the second most important greenhouse gas after carbon dioxide, and is responsible for about 20% of the global warming effect since pre-industrial times. Rice paddies are the largest anthropogenic methane source and produce 7-17% of atmospheric methane. Warm waterlogged soil and exuded nutrients from rice roots provide ideal conditions for methanogenesis in paddies with annual methane emissions of 25-100-million tonnes. This scenario will be exacerbated by an expansion in rice cultivation needed to meet the escalating demand for food in the coming decades. There is an urgent need to establish sustainable technologies for increasing rice production while reducing methane fluxes from rice paddies. However, ongoing efforts for methane mitigation in rice paddies are mainly based on farming practices and measures that are difficult to implement. Despite proposed strategies to increase rice productivity and reduce methane emissions, no high-starch low-methane-emission rice has been developed. Here we show that the addition of a single transcription factor gene, barley SUSIBA2 (refs 7, 8), conferred a shift of carbon flux to SUSIBA2 rice, favouring the allocation of photosynthates to aboveground biomass over allocation to roots. The altered allocation resulted in an increased biomass and starch content in the seeds and stems, and suppressed methanogenesis, possibly through a reduction in root exudates. Three-year field trials in China demonstrated that the cultivation of SUSIBA2 rice was associated with a significant reduction in methane emissions and a decrease in rhizospheric methanogen levels. SUSIBA2 rice offers a sustainable means of providing increased starch content for food production while reducing greenhouse gas emissions from rice cultivation. Approaches to increase rice productivity and reduce methane emissions as seen in SUSIBA2 rice may be particularly beneficial in a future climate with rising temperatures resulting in increased methane emissions from paddies.
Collapse
|
309
|
Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia 2015; 30:173-81. [PMID: 26165234 DOI: 10.1038/leu.2015.180] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2014] [Revised: 06/28/2015] [Accepted: 06/29/2015] [Indexed: 12/14/2022]
Abstract
Bruton's tyrosine kinase (BTK) kinase is a member of the TEC kinase family and is a key regulator of the B-cell receptor (BCR)-mediated signaling pathway. It is important for B-cell maturation, proliferation, survival and metastasis. Pharmacological inhibition of BTK is clinically effective against a variety of B-cell malignances, such as mantle cell lymphoma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and activated B-cell-diffuse large B-cell lymphoma. MNK kinase is one of the key downstream regulators in the RAF-MEK-ERK signaling pathway and controls protein synthesis via regulating the activity of eIF4E. Inhibition of MNK activity has been observed to moderately inhibit the proliferation of AML cells. Through a structure-based drug-design approach, we have discovered a selective and potent BTK/MNK dual kinase inhibitor (QL-X-138), which exhibits covalent binding to BTK and noncovalent binding to MNK. Compared with the BTK kinase inhibitor (PCI-32765) and the MNK kinase inhibitor (cercosporamide), QL-X-138 enhanced the antiproliferative efficacies in vitro against a variety of B-cell cancer cell lines, as well as AML and CLL primary patient cells, which respond moderately to BTK inhibitor in vitro. The agent can effectively arrest the growth of lymphoma and leukemia cells at the G0-G1 stage and can induce strong apoptotic cell death. These primary results demonstrate that simultaneous inhibition of BTK and MNK kinase activity might be a new therapeutic strategy for B-cell malignances.
Collapse
|
310
|
Ablikim M, Achasov MN, Ai XC, Albayrak O, Albrecht M, Ambrose DJ, Amoroso A, An FF, An Q, Bai JZ, Baldini Ferroli R, Ban Y, Bennett DW, Bennett JV, Bertani M, Bettoni D, Bian JM, Bianchi F, Boger E, Bondarenko O, Boyko I, Briere RA, Cai H, Cai X, Cakir O, Calcaterra A, Cao GF, Cetin SA, Chang JF, Chelkov G, Chen G, Chen HS, Chen HY, Chen JC, Chen ML, Chen SJ, Chen X, Chen XR, Chen YB, Cheng HP, Chu XK, Cibinetto G, Cronin-Hennessy D, Dai HL, Dai JP, Dbeyssi A, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Du SX, Duan PF, Fan JZ, Fang J, Fang SS, Fang X, Fang Y, Fava L, Feldbauer F, Felici G, Feng CQ, Fioravanti E, Fritsch M, Fu CD, Gao Q, Gao Y, Gao Z, Garzia I, Geng C, Goetzen K, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo Y, Guo YP, Haddadi Z, Hafner A, Han S, Han YL, Hao XQ, Harris FA, He KL, He ZY, Held T, Heng YK, Hou ZL, Hu C, Hu HM, Hu JF, Hu T, Hu Y, Huang GM, Huang GS, Huang HP, Huang JS, Huang XT, Huang Y, Hussain T, Ji Q, Ji QP, Ji XB, Ji XL, Jiang LL, Jiang LW, Jiang XS, Jiao JB, Jiao Z, Jin DP, Jin S, Johansson T, Julin A, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kavatsyuk M, Ke BC, Kliemt R, Kloss B, Kolcu OB, Kopf B, Kornicer M, Kuehn W, Kupsc A, Lai W, Lange JS, Lara M, Larin P, Leng C, Li CH, Li C, Li DM, Li F, Li G, Li HB, Li JC, Li J, Li K, Li K, Li L, Li PR, Li T, Li WD, Li WG, Li XL, Li XM, Li XN, Li XQ, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Lin DX, Liu BJ, Liu CX, Liu FH, Liu F, Liu F, Liu HB, Liu HH, Liu HH, Liu HM, Liu J, Liu JP, Liu JY, Liu K, Liu KY, Liu LD, Liu PL, Liu Q, Liu SB, Liu X, Liu XX, Liu YB, Liu ZA, Liu Z, Liu Z, Loehner H, Lou XC, Lu HJ, Lu JG, Lu RQ, Lu Y, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lv M, Lyu XR, Ma FC, Ma HL, Ma LL, Ma QM, Ma S, Ma T, Ma XN, Ma XY, Maas FE, Maggiora M, Malik QA, Mao YJ, Mao ZP, Marcello S, Messchendorp JG, Min J, Min TJ, Mitchell RE, Mo XH, Mo YJ, Morales Morales C, Moriya K, Muchnoi NY, Muramatsu H, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu SL, Niu XY, Olsen SL, Ouyang Q, Pacetti S, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Poling R, Pu YN, Qi M, Qian S, Qiao CF, Qin LQ, Qin N, Qin XS, Qin Y, Qin ZH, Qiu JF, Rashid KH, Redmer CF, Ren HL, Ripka M, Rong G, Ruan XD, Santoro V, Sarantsev A, Savrié M, Schoenning K, Schumann S, Shan W, Shao M, Shen CP, Shen PX, Shen XY, Sheng HY, Song WM, Song XY, Sosio S, Spataro S, Sun GX, Sun JF, Sun SS, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Tapan I, Thorndike EH, Tiemens M, Toth D, Ullrich M, Uman I, Varner GS, Wang B, Wang BL, Wang D, Wang DY, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang QJ, Wang SG, Wang W, Wang XF, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZH, Wang ZY, Weber T, Wei DH, Wei JB, Weidenkaff P, Wen SP, Wiedner U, Wolke M, Wu LH, Wu Z, Xia LG, Xia Y, Xiao D, Xiao ZJ, Xie YG, Xiu QL, Xu GF, Xu L, Xu QJ, Xu QN, Xu XP, Yan L, Yan WB, Yan WC, Yan YH, Yang HX, Yang L, Yang Y, Yang YX, Ye H, Ye M, Ye MH, Yin JH, Yu BX, Yu CX, Yu HW, Yu JS, Yuan CZ, Yuan WL, Yuan Y, Yuncu A, Zafar AA, Zallo A, Zeng Y, Zhang BX, Zhang BY, Zhang C, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang K, Zhang L, Zhang SH, Zhang XY, Zhang Y, Zhang YH, Zhang YT, Zhang ZH, Zhang ZP, Zhang ZY, Zhao G, Zhao JW, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao QW, Zhao SJ, Zhao TC, Zhao YB, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhou L, Zhou L, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu K, Zhu KJ, Zhu S, Zhu XL, Zhu YC, Zhu YS, Zhu ZA, Zhuang J, Zotti L, Zou BS, Zou JH. Observation of the ψ(1 3D2) State in e+e-→π+π-γχc1 at BESIII. PHYSICAL REVIEW LETTERS 2015; 115:011803. [PMID: 26182091 DOI: 10.1103/physrevlett.115.011803] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Indexed: 06/04/2023]
Abstract
We report the observation of the X(3823) state in the process e+e-→π+π-X(3823)→π+π-γχc1 with a statistical significance of 6.2σ, in data samples at center-of-mass energies sqrt[s]=4.230, 4.260, 4.360, 4.420, and 4.600 GeV collected with the BESIII detector at the BEPCII electron positron collider. The measured mass of the X(3823) state is (3821.7±1.3±0.7) MeV/c2, where the first error is statistical and the second systematic, and the width is less than 16 MeV at the 90% confidence level. The products of the Born cross sections for e+e-→π+π-X(3823) and the branching ratio B[X(3823)→γχc1,c2] are also measured. These measurements are in good agreement with the assignment of the X(3823) state as the ψ(1 3D2) charmonium state.
Collapse
|
311
|
Cui S, Guo L, Li X, Gu Y, Fu J, Dong L, Song H, Chen X, Lu Y, Hu C, Xiao F, Zhu D, Wu Z, Zhang Q. Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia. Eur J Vasc Endovasc Surg 2015; 50:494-501. [PMID: 26122834 DOI: 10.1016/j.ejvs.2015.05.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 05/20/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease and a major unmet public health care need. This phase I clinical study was performed to assess the safety and preliminary efficacy of naked plasmid DNA (pUDK-HGF) expressing human hepatocyte growth factor (HGF) in patients with critical limb ischemia (CLI). DESIGN Twenty-one patients with CLI were enrolled and randomly divided into four dose groups (4-16 mg) to receive local injection of pUDK-HGF into ischemic calf and/or thigh muscles twice on days 1 and 15. Safety, including adverse events and physiological parameters, and preliminary efficacy, including pain severity score (VAS), ulcer size, transcutaneous oxygen pressure (TcPO2), and ankle brachial index (ABI), were evaluated throughout a 3 month follow up period. RESULTS All doses of pUDK-HGF were well tolerated by the patients. None of the adverse effects was considered to be related to pUDK-HGF injection. Two significant clinical results were observed after pUDK-HGF administration. The mean VAS value of all patients decreased from 4.52 at baseline to 0.30 (p < .01), and pain had disappeared in 14 out of 17 evaluable patients by day 91. Two of four ulcers had completely healed, with the other two patients having more than 25% ulcer size reduction in the long axis diameter. Of five patients with gangrene, one gangrenous wound had healed completely and two patients showed marked size reduction by day 91. The mean hemodynamic parameters (ABI, TcPO2) were also improved. CONCLUSION Intramuscular injection of pUDK-HGF is safe, and may provide symptomatic relief for CLI patients. A larger, randomized, double blinded phase II trial will provide more information on safety and efficacy.
Collapse
|
312
|
Wells A, Edwards C, Adebajo A, Kivitz A, Bird P, Shah K, Hu C, Aelion J. SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2896] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
313
|
Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, McIlraith M, Hu C, Edwards C, Birbara C, Mease P. OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3594] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
314
|
Yu J, Gong Y, Bar-Ad V, Giaddui T, Hu C, Gore E, Wheatley M, Witt J, Robinson C, Kong F, Bradley J, Galvin J, Xiao Y. SU-E-J-134: Optimizing Technical Parameters for Using Atlas Based Automatic Segmentation for Evaluation of Contour Accuracy Experience with Cardiac Structures From NRG Oncology/RTOG 0617. Med Phys 2015. [DOI: 10.1118/1.4924220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
315
|
Papp K, Crowley J, Paul C, Gooderham M, Reich K, Hu C, Day R, Griffiths C. THU0413 Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis (Esteem 1 and 2). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
316
|
Kavanaugh A, Adebajo A, Gladman D, Gomez-Reino J, Hall S, Lespessailles E, Mease P, Schett G, Shah K, Hu C, Wollenhaupt J. THU0420 Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomised, Controlled Trial and Open-Label Extension (Palace 1). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2907] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
317
|
Edwards C, Blanco F, Crowley J, Hu C, Shah K, Birbara C. THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3). Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2889] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
318
|
Weiss C, Arepally A, Paudel K, Singh J, Hu C, Shin E, Anders R, Moran T, Kraitchman D. Bariatric embolization using large calibrated spheres (300-500 μm): safety and long-term efficacy in a swine model. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2015.01.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
319
|
Ablikim M, Achasov MN, Ai XC, Albayrak O, Albrecht M, Ambrose DJ, Amoroso A, An FF, An Q, Bai JZ, Ferroli RB, Ban Y, Bennett DW, Bennett JV, Bertani M, Bettoni D, Bian JM, Bianchi F, Boger E, Bondarenko O, Boyko I, Briere RA, Cai H, Cai X, Cakir O, Calcaterra A, Cao GF, Cetin SA, Chang JF, Chelkov G, Chen G, Chen HS, Chen HY, Chen JC, Chen ML, Chen SJ, Chen X, Chen XR, Chen YB, Cheng HP, Chu XK, Chu YP, Cibinetto G, Cronin-Hennessy D, Dai HL, Dai JP, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Du SX, Duan PF, Fan JZ, Fang J, Fang SS, Fang X, Fang Y, Fava L, Feldbauer F, Felici G, Feng CQ, Fioravanti E, Fu CD, Gao Q, Gao Y, Garzia I, Goetzen K, Gong WX, Gradl W, Greco M, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo T, Guo Y, Guo YP, Haddadi Z, Hafner A, Han S, Han YL, Harris FA, He KL, He ZY, Held T, Heng YK, Hou ZL, Hu C, Hu HM, Hu JF, Hu T, Hu Y, Huang GM, Huang GS, Huang HP, Huang JS, Huang XT, Huang Y, Hussain T, Ji Q, Ji QP, Ji XB, Ji XL, Jiang LL, Jiang LW, Jiang XS, Jiao JB, Jiao Z, Jin DP, Jin S, Johansson T, Julin A, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kavatsyuk M, Ke BC, Kliemt R, Kloss B, Kolcu OB, Kopf B, Kornicer M, Kuehn W, Kupsc A, Lai W, Lange JS, Lara M, Larin P, Li C, Li CH, Li DM, Li F, Li G, Li HB, Li JC, Li J, Li K, Li K, Li PR, Li T, Li WD, Li WG, Li XL, Li XM, Li XN, Li XQ, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Lin DX, Liu BJ, Liu CL, Liu CX, Liu FH, Liu F, Liu F, Liu HB, Liu HH, Liu HH, Liu HM, Liu J, Liu JP, Liu JY, Liu K, Liu KY, Liu LD, Liu Q, Liu SB, Liu X, Liu XX, Liu YB, Liu ZA, Liu Z, Liu Z, Loehner H, Lou XC, Lu HJ, Lu JG, Lu RQ, Lu Y, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Lv M, Lyu XR, Ma FC, Ma HL, Ma LL, Ma QM, Ma S, Ma T, Ma XN, Ma XY, Maas FE, Maggiora M, Malik QA, Mao YJ, Mao ZP, Marcello S, Messchendorp JG, Min J, Min TJ, Mitchell RE, Mo XH, Mo YJ, Moeini H, Morales CM, Moriya K, Muchnoi NY, Muramatsu H, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu SL, Niu XY, Olsen SL, Ouyang Q, Pacetti S, Patteri P, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Poling R, Pu YN, Qi M, Qian S, Qiao CF, Qin LQ, Qin N, Qin XS, Qin Y, Qin ZH, Qiu JF, Rashid KH, Redmer CF, Ren HL, Ripka M, Rong G, Ruan XD, Santoro V, Sarantsev A, Savrié M, Schoenning K, Schumann S, Shan W, Shao M, Shen CP, Shen PX, Shen XY, Sheng HY, Shepherd MR, Song WM, Song XY, Sosio S, Spataro S, Spruck B, Sun GX, Sun JF, Sun SS, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Tapan I, Thorndike EH, Tiemens M, Toth D, Ullrich M, Uman I, Varner GS, Wang B, Wang BL, Wang D, Wang DY, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang QJ, Wang SG, Wang W, Wang XF, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZH, Wang ZY, Wei DH, Wei JB, Weidenkaff P, Wen SP, Wiedner U, Wolke M, Wu LH, Wu Z, Xia LG, Xia Y, Xiao D, Xiao ZJ, Xie YG, Xiu QL, Xu GF, Xu L, Xu QJ, Xu QN, Xu XP, Yan L, Yan WB, Yan WC, Yan YH, Yang HX, Yang L, Yang Y, Yang YX, Ye H, Ye M, Ye MH, Yin JH, Yu BX, Yu CX, Yu HW, Yu JS, Yuan CZ, Yuan WL, Yuan Y, Yuncu A, Zafar AA, Zallo A, Zeng Y, Zhang BX, Zhang BY, Zhang C, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang K, Zhang L, Zhang SH, Zhang XJ, Zhang XY, Zhang Y, Zhang YH, Zhang ZH, Zhang ZP, Zhang ZY, Zhao G, Zhao JW, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao QW, Zhao SJ, Zhao TC, Zhao YB, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhou L, Zhou L, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu K, Zhu KJ, Zhu S, Zhu XL, Zhu YC, Zhu YS, Zhu ZA, Zhuang J, Zou BS, Zou JH. Study of e(+)e(-)→ωχ(cJ) at center of mass energies from 4.21 to 4.42 GeV. PHYSICAL REVIEW LETTERS 2015; 114:092003. [PMID: 25793804 DOI: 10.1103/physrevlett.114.092003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Indexed: 06/04/2023]
Abstract
Based on data samples collected with the BESIII detector at the BEPCII collider at nine center of mass energies from 4.21 to 4.42 GeV, we search for the production of e^{+}e^{-}→ωχ_{cJ} (J=0, 1, 2). The process e^{+}e^{-}→ωχ_{c0} is observed for the first time, and the Born cross sections at sqrt[s]=4.23 and 4.26 GeV are measured to be (55.4±6.0±5.9) and (23.7±5.3±3.5) pb, respectively, where the first uncertainties are statistical and the second are systematic. The ωχ_{c0} signals at the other seven energies and the e^{+}e^{-}→ωχ_{c1} and ωχ_{c2} signals are not significant, and the upper limits on the cross sections are determined. By examining the ωχ_{c0} cross section as a function of center of mass energy, we find that it is inconsistent with the line shape of the Y(4260) observed in e^{+}e^{-}→π^{+}π^{-}J/ψ. Assuming the ωχ_{c0} signals come from a single resonance, we extract the mass and width of the resonance to be (4230±8±6) MeV/c^{2} and (38±12±2) MeV, respectively, and the statistical significance is more than 9σ.
Collapse
|
320
|
Wang Y, Wang M, Li J, Yao S, Xue J, Zou W, Hu C. Determination of spectinomycin and related substances by HPLC coupled with evaporative light scattering detection. ACTA CHROMATOGR 2015. [DOI: 10.1556/achrom.27.2015.1.8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
321
|
Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med 2015; 16:176-83. [PMID: 25407158 PMCID: PMC4320673 DOI: 10.1111/hiv.12195] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/22/2014] [Indexed: 10/24/2022]
Abstract
OBJECTIVES Pregnancy results in physiological changes altering the pharmacokinetics of drugs metabolized by cytochrome P450 3A4 (CYP3A4). The urinary ratio of 6-β hydroxycortisol to cortisol (6βHF : F) is a marker of CYP3A4 induction. We sought to evaluate its change in antiretroviral (ARV)-treated HIV-1-infected women and to relate this change to ARV pharmacokinetics. METHODS Women receiving various ARVs had pharmacokinetic evaluations during the third trimester of pregnancy (>30 weeks) and postpartum with determination of 6βHF : F carried out on the same days. The Wilcoxon signed rank test was used to compare the ratio antepartum to postpartum. The relationship between the change in ratio and the change in pharmacokinetics was analysed using Kendall's tau. RESULTS 6βHF : F ratios were available for 107 women antepartum, with 54 having postpartum values. The ratio was higher antepartum (P=0.033) (median comparison 1.35; 95% confidence interval 1.01, 1.81). For 71 women taking a protease inhibitor (PI), the antepartum vs. postpartum 6βHF : F comparison was marginally significant (P=0.058). When the change in the 6βHF : F ratio was related to the change in the dose-adjusted ARV area under the plasma concentration vs. time curve (AUC) between antepartum and postpartum, the 35 subjects in the lopinavir/ritonavir (LPV/r) arms demonstrated an inverse relationship (P=0.125), albeit this correlation did not reach statistical significance. CONCLUSIONS A 35% increase in the urinary 6βHF : F ratio was measured during late pregnancy compared with postpartum, indicating that CYP3A induction occurs during pregnancy. The trend towards an inverse relationship between the change in the 6βHF : F ratio and the change in the LPV AUC antepartum vs. postpartum suggests that CYP3A induction may be one mechanism behind altered LPV exposure during pregnancy.
Collapse
|
322
|
Wu C, Hsieh P, Fan Jiang J, Shih H, Chen C, Hu C. A positive bacterial culture from allograft bone at implantation does not correlate with subsequent surgical site infection. Bone Joint J 2015; 97-B:427-31. [DOI: 10.1302/0301-620x.97b3.34600] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Fresh-frozen allograft bone is frequently used in orthopaedic surgery. We investigated the incidence of allograft-related infection and analysed the outcomes of recipients of bacterial culture-positive allografts from our single-institute bone bank during bone transplantation. The fresh-frozen allografts were harvested in a strict sterile environment during total joint arthroplasty surgery and immediately stored in a freezer at -78º to -68º C after packing. Between January 2007 and December 2012, 2024 patients received 2083 allografts with a minimum of 12 months of follow-up. The overall allograft-associated infection rate was 1.2% (24/2024). Swab cultures of 2083 allografts taken before implantation revealed 21 (1.0%) positive findings. The 21 recipients were given various antibiotics at the individual orthopaedic surgeon’s discretion. At the latest follow-up, none of these 21 recipients displayed clinical signs of infection following treatment. Based on these findings, we conclude that an incidental positive culture finding for allografts does not correlate with subsequent surgical site infection. Additional prolonged post-operative antibiotic therapy may not be necessary for recipients of fresh-frozen bone allograft with positive culture findings. Cite this article: Bone Joint J 2015;97-B:427–31.
Collapse
|
323
|
Ablikim M, Achasov M, Ai X, Albayrak O, Albrecht M, Ambrose D, Amoroso A, An F, An Q, Bai J, Baldini Ferroli R, Ban Y, Bennett D, Bennett J, Bertani M, Bettoni D, Bian J, Bianchi F, Boger E, Bondarenko O, Boyko I, Briere R, Cai H, Cai X, Cakir O, Calcaterra A, Cao G, Cetin S, Chang J, Chelkov G, Chen G, Chen H, Chen H, Chen J, Chen M, Chen S, Chen X, Chen X, Chen Y, Cheng H, Chu X, Cibinetto G, Cronin-Hennessy D, Dai H, Dai J, Dbeyssi A, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Du S, Duan P, Fan J, Fang J, Fang S, Fang X, Fang Y, Fava L, Feldbauer F, Felici G, Feng C, Fioravanti E, Fritsch M, Fu C, Gao Q, Gao Y, Garzia I, Goetzen K, Gong W, Gradl W, Greco M, Gu M, Gu Y, Guan Y, Guo A, Guo L, Guo T, Guo Y, Guo Y, Haddadi Z, Hafner A, Han S, Han Y, Harris F, He K, He Z, Held T, Heng Y, Hou Z, Hu C, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang G, Huang H, Huang J, Huang X, Huang Y, Hussain T, Ji Q, Ji Q, Ji X, Ji X, Jiang L, Jiang L, Jiang X, Jiao J, Jiao Z, Jin D, Jin S, Johansson T, Julin A, Kalantar-Nayestanaki N, Kang X, Kang X, Kavatsyuk M, Ke B, Kliemt R, Kloss B, Kolcu O, Kopf B, Kornicer M, Kuehn W, Kupsc A, Lai W, Lange J, Lara M, Larin P, Li C, Li C, Li D, Li F, Li G, Li H, Li J, Li J, Li K, Li K, Li P, Li T, Li W, Li W, Li X, Li X, Li X, Li X, Li Z, Liang H, Liang Y, Liang Y, Liao G, Lin D, Liu B, Liu C, Liu C, Liu F, Liu F, Liu F, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu L, Liu P, Liu Q, Liu S, Liu X, Liu X, Liu Y, Liu Z, Liu Z, Liu Z, Loehner H, Lou X, Lu H, Lu J, Lu R, Lu Y, Lu Y, Luo C, Luo M, Luo T, Luo X, Lv M, Lyu X, Ma F, Ma H, Ma L, Ma Q, Ma S, Ma T, Ma X, Ma X, Maas F, Maggiora M, Malik Q, Mao Y, Mao Z, Marcello S, Messchendorp J, Min J, Min T, Mitchell R, Mo X, Mo Y, Morales Morales C, Moriya K, Muchnoi N, Muramatsu H, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Niu S, Niu X, Olsen S, Ouyang Q, Pacetti S, Patteri P, Pelizaeus M, Peng H, Peters K, Ping J, Ping R, Poling R, Pu Y, Qi M, Qian S, Qiao C, Qin L, Qin N, Qin X, Qin Y, Qin Z, Qiu J, Rashid K, Redmer C, Ren H, Ripka M, Rong G, Ruan X, Santoro V, Sarantsev A, Savrié M, Schoenning K, Schumann S, Shan W, Shao M, Shen C, Shen P, Shen X, Sheng H, Shepherd M, Song W, Song X, Sosio S, Spataro S, Spruck B, Sun G, Sun J, Sun S, Sun Y, Sun Y, Sun Z, Sun Z, Tang C, Tang X, Tapan I, Thorndike E, Tiemens M, Toth D, Ullrich M, Uman I, Varner G, Wang B, Wang B, Wang D, Wang D, Wang K, Wang L, Wang L, Wang M, Wang P, Wang P, Wang Q, Wang S, Wang W, Wang X, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Weber T, Wei D, Wei J, Weidenkaff P, Wen S, Wiedner U, Wolke M, Wu L, Wu Z, Xia L, Xia Y, Xiao D, Xiao Z, Xie Y, Xu G, Xu L, Xu Q, Xu Q, Xu X, Yan L, Yan W, Yan W, Yan Y, Yang H, Yang L, Yang Y, Yang Y, Ye H, Ye M, Ye M, Yin J, Yu B, Yu C, Yu H, Yu J, Yuan C, Yuan W, Yuan Y, Yuncu A, Zafar A, Zallo A, Zeng Y, Zhang B, Zhang B, Zhang C, Zhang C, Zhang D, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang K, Zhang L, Zhang S, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao Q, Zhao S, Zhao T, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng W, Zheng Y, Zhong B, Zhou L, Zhou L, Zhou X, Zhou X, Zhou X, Zhou X, Zhu K, Zhu K, Zhu S, Zhu X, Zhu Y, Zhu Y, Zhu Z, Zhuang J, Zou B, Zou J. Precision measurement of theD*0decay branching fractions. Int J Clin Exp Med 2015. [DOI: 10.1103/physrevd.91.031101] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
324
|
Weiss C, Holly B, Arepally A, Singh J, Paudel K, Hu C, Mao H, Wang J, Kraitchman D. Recanalization/collateralization after bariatric embolization in a swine model: potential implications for future bariatric surgery. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2014.12.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
325
|
Yan J, Hu C, Jiang F, Zhang R, Wang J, Tang S, Peng D, Chen M, Bao Y, Jia W. Genetic variants of PLA2G6 are associated with Type 2 diabetes mellitus and triglyceride levels in a Chinese population. Diabet Med 2015; 32:280-6. [PMID: 25207958 DOI: 10.1111/dme.12587] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Revised: 07/15/2014] [Accepted: 09/01/2014] [Indexed: 01/24/2023]
Abstract
AIM To test the association of PLA2G6 variants with Type 2 diabetes and clinical characteristics in large Chinese population-based samples. METHODS A total of 6822 people were recruited. In the first stage, 15 single nucleotide polymorphisms within the PLA2G6 region were selected and genotyped in 3700 Chinese Han people. In the second stage, the single nucleotide polymorphisms that showed a significant association were genotyped in an additional 3122 samples for replication. Genotype-phenotype association studies and meta-analyses were performed after combining data from the two stages. RESULTS In the first stage, we detected rs132984 and rs2284060 as significantly associated with Type 2 diabetes with odds ratios of 1.247 (95% CI 1.074-1.449, P = 0.004, empirical P = 0.047) and 1.173 (95% CI 1.059-1.299, P = 0.002, empirical P = 0.029), respectively. In the second stage, a similar effect of rs132984 on Type 2 diabetes was observed (odds ratio 1.280, 95% CI 1.094-1.497, P = 0.002). The meta-analysis showed a significant effect of the two single nucleotide polymorphisms on Type 2 diabetes (odds ratio 1.254, 95% CI 1.104-1.451, P = 4.85 × 10⁻⁵ for rs132984; odds ratio 1.120, 95% CI 1.046-1.195, P = 0.003 for rs2284060). Moreover, genotype-phenotype association analysis showed that rs132984 was associated with triglyceride levels (P = 0.022, empirical P = 0.044) and area under the curve for glucose (P = 0.015, empirical P = 0.030). CONCLUSIONS Our data imply that common single nucleotide polymorphisms within the PLA2G6 region are associated with Type 2 diabetes and triglyceride levels in the Chinese population.
Collapse
|